The assembly line of pediatric neurodiversity in England has reached a breaking point. For-profit clinics are churning out ADHD diagnoses with a speed that defies clinical logic, often bypassing the deep developmental history required to distinguish a neurological condition from the symptoms of trauma, sleep deprivation, or anxiety. This isn't just a matter of administrative backlog. It is a fundamental shift in how we treat the developing brain, where the pressure of a two-year NHS waiting list has forced desperate parents into a private market that prioritizes throughput over long-term pediatric safety.
Doctors are now sounding the alarm because the current regulatory framework, overseen by the Care Quality Commission (CQC), was never designed to handle a surge of this magnitude. When a child is misdiagnosed, the consequences are not merely academic. They are pharmacological. We are seeing a generation of children initiated on potent stimulants by clinicians who may never see them again, leaving GPs to manage complex medication regimes they feel unqualified to supervise.
The Private High Speed Rail to Diagnosis
The current crisis in ADHD care is a failure of both the public and private sectors. While the NHS faces an unprecedented spike in referrals, the private sector has stepped in with a business model that looks more like a logistics company than a healthcare provider. These clinics often rely on a "remote-first" assessment model that can conclude a life-altering diagnosis in under an hour.
A thorough ADHD assessment for a child is supposed to be a slow, methodical process. It requires corroborating evidence from schools, a detailed birth and developmental history, and a physical examination to rule out cardiac issues or other underlying conditions. In the rush to clear the backlog, some private providers are cutting these corners. They argue they are simply filling a void left by a starved public health system.
The reality is more cynical. By focusing on a high volume of assessments, these clinics generate massive upfront fees while shedding the expensive, labor-intensive responsibility of long-term follow-up care. Once the diagnosis is handed over and the initial titration of medication begins, the child is often discharged back to their GP under "Shared Care Agreements."
The Shared Care Trap for GPs
A Shared Care Agreement is supposed to be a partnership. The specialist provides the expertise and the diagnosis, while the GP handles the ongoing prescriptions and basic monitoring. But in the current climate, these agreements have become a source of immense professional tension and clinical risk.
Many GPs are now refusing to sign these agreements. They argue that the quality of private assessments is so poor that they cannot, in good conscience, take clinical responsibility for the powerful stimulants being prescribed. When a GP refuses a Shared Care Agreement, the family is left in a devastating limbo. They can either pay hundreds of pounds a month for private prescriptions or join the back of the NHS queue they were trying to avoid in the first place.
The tension is exacerbated by the nature of the medications involved. Methylphenidate and lisdexamfetamine are controlled substances. They require careful monitoring of blood pressure, heart rate, and growth velocity. If a child’s heart rate spikes or their weight drops, who is responsible for adjusting the dose? The private clinic that did the one-hour Zoom call six months ago? Or the GP who has never seen the child’s specialist records?
Why Regulation is Failing the Most Vulnerable
The CQC is the body tasked with ensuring these clinics meet basic standards. However, the CQC often looks at "systems and processes" rather than the clinical validity of individual diagnoses. A clinic can have a perfect digital filing system and a robust complaints procedure while still delivering dangerously superficial assessments.
The regulatory gap is particularly wide when it comes to "online-only" providers. These entities can base their headquarters in one region and treat children across the entire country. This geographic detachment makes it almost impossible for clinicians to understand the local context of a child’s life, such as the quality of support available in their specific school or the environmental factors contributing to their behavior.
The Problem of Diagnostic Overshadowing
When a clinician is incentivized to find ADHD, they will find it. This is known as diagnostic overshadowing, where every struggle a child faces is viewed through the lens of a single condition. A child who has experienced trauma or who lives in a chaotic household may present with hyperactivity and a lack of focus. If the assessment doesn't include a robust look at the child's social and emotional history, they may be given a pill for a neurological condition they don't have, while the underlying cause of their distress remains unaddressed.
Recent data suggests that the youngest children in a classroom are significantly more likely to be diagnosed with ADHD than their older peers. This "relative age effect" is a clear indicator that normal developmental immaturity is being medicalized. In a high-speed private clinic, these nuances are often the first things to be discarded.
The Pharmaceutical Pipeline
The shift toward private diagnosis has also created a lucrative pipeline for pharmaceutical companies. Global shortages of ADHD medication have dominated headlines over the last year, but less attention has been paid to the sheer volume of new prescriptions being written. In England, the number of people receiving ADHD medication has more than doubled in the last five years.
While medication can be life-changing for children with severe ADHD, it is not a cure-all. It is meant to be part of a "multimodal" treatment plan that includes behavioral therapy, parental support, and school accommodations. In the private model, the medication is often the only thing the child actually receives. The therapy and the support are "recommended" in the report, but they are rarely provided by the clinic and are almost impossible to access via the NHS.
The Cost of a False Positive
The long-term impact of misdiagnosis is not well-documented because we are currently in the middle of a massive, unregulated experiment. We do know that stimulants can have side effects on sleep, appetite, and mood. For a child who actually has ADHD, these risks are balanced against the benefit of being able to function and learn. For a child who was misdiagnosed, there is no benefit—only the risk.
There is also the psychological impact of the label itself. A child who is told their brain is "broken" or "different" at age seven may carry that identity into adulthood, potentially limiting their own sense of agency and resilience. When that label is applied after a 45-minute video call, the medical profession has failed that child.
Restoring Clinical Integrity
Fixing this crisis requires more than just more funding for the NHS. It requires a fundamental re-evaluation of how we regulate private neurodiversity services.
First, the CQC needs the power and the expertise to conduct "deep dive" audits into the clinical quality of assessments. This means looking at the evidence used to reach a diagnosis, not just whether the paperwork was signed on time.
Second, the "Shared Care" model needs to be overhauled. It is unfair to expect GPs to act as the safety net for a private industry that is cutting corners. There should be a national standard for what constitutes a valid ADHD assessment, and private clinics should be held to the same rigorous multidisciplinary standards as the best NHS services.
Third, we must move away from the "diagnosis-first" model of support. Currently, a diagnosis is often the only way a child can get help in school. This creates a desperate incentive for parents to seek any diagnosis they can get. If support were based on a child's observable needs—rather than a medical label—the pressure on the diagnostic pipeline would ease overnight.
The current state of pediatric ADHD care in England is a cautionary tale of what happens when healthcare is treated as a commodity. We have created a system where the speed of the transaction is valued more than the health of the patient. For the thousands of children currently being funneled through these high-volume clinics, the cost of that efficiency may be felt for decades to come.
Demanding a return to slow, careful, and holistic medicine is not a luxury. It is a necessity for the safety of our children.
